Cargando…

Development of PET Radioligands Targeting COX-2 for Colorectal Cancer Staging, a Review of in vitro and Preclinical Imaging Studies

Colorectal cancer (CRC) is the second most common cause of cancer death, making early diagnosis a major public health challenge. The role of inflammation in tumorigenesis has been extensively explored, and among the identified markers of inflammation, cyclooxygenase-2 (COX-2) expression seems to be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dagallier, Caroline, Avry, François, Touchefeu, Yann, Buron, Frédéric, Routier, Sylvain, Chérel, Michel, Arlicot, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217454/ https://www.ncbi.nlm.nih.gov/pubmed/34169083 http://dx.doi.org/10.3389/fmed.2021.675209

Ejemplares similares

Design of selective COX-2 inhibitors in the (aza)indazole series. Chemistry, in vitro studies, radiochemistry and evaluations in rats of a [(18)F] PET tracer
por: Elie, Jonathan, et al.
Publicado: (2018)

Preclinical characterization of [(18)F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase
por: Koike, Tatsuki, et al.
Publicado: (2021)

Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches
por: Bodet-Milin, Caroline, et al.
Publicado: (2019)

Modeling Temperature and Species Concentration Profiles on a Continuous-Flow Reactor Applied to Aldol Condensation
por: Chairat, Aziza, et al.
Publicado: (2022)

Sensitivity of pretargeted immunoPET using (68)Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with (18)FDG PET-CT
por: Foubert, Fanny, et al.
Publicado: (2018)

The Azaindole Framework in the Design of Kinase Inhibitors
por: Mérour, Jean-Yves, et al.
Publicado: (2014)

Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington’s disease
por: Bertoglio, Daniele, et al.
Publicado: (2021)

Aminations and arylations by direct C–O activation for the design of 7,8-dihydro-6H-5,8-ethanopyrido[3,2-d]pyrimidines
por: Laurent, Mazarine, et al.
Publicado: (2021)

Fluorine-18 Labelled Radioligands for PET Imaging of Cyclooxygenase-2
por: Kaur, Jatinder, et al.
Publicado: (2022)

30ièmes Journées Franco-Belges de Pharmacochimie
por: Aci-Sèche, Samia, et al.
Publicado: (2016)

Design, Synthesis and the Biological Evaluation of New 1,3-Thiazolidine-4-ones Based on the 4-Amino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one Scaffold
por: Apotrosoaei, Maria, et al.
Publicado: (2014)

Access and Modulation of Substituted Pyrrolo[3,4-c]pyrazole-4,6-(2H,5H)-diones
por: Ejjoummany, Abdelaziz, et al.
Publicado: (2023)

Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks
por: Dupont, Anne-Claire, et al.
Publicado: (2023)

Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging α-Synuclein
por: Zhang, Xiang, et al.
Publicado: (2014)

Development of a PET radioligand for potassium channels to image CNS demyelination
por: Brugarolas, Pedro, et al.
Publicado: (2018)

A novel antioxidant ergothioneine PET radioligand for in vivo imaging applications
por: Behof, William J., et al.
Publicado: (2021)

Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology
por: Barbet, Jacques, et al.
Publicado: (2017)

Synthesis and Biological Evaluation of New 1,3-Thiazolidine-4-one Derivatives of 2-(4-Isobutylphenyl)propionic Acid
por: Vasincu, Ioana Mirela, et al.
Publicado: (2014)

Synthesis of novel series of 3,5-disubstituted imidazo[1,2-d] [1,2,4]thiadiazoles involving S(N)Ar and Suzuki–Miyaura cross-coupling reactions
por: Pescheteau, Clémentine, et al.
Publicado: (2022)

Regioselective Synthesis of New 2,4-(Het)aryl-3H-pyrido[1′,2′:1,5]pyrazolo[4,3-d]pyrimidines Involving Palladium-Catalyzed Cross-Coupling Reactions
por: Ejjoummany, Abdelaziz, et al.
Publicado: (2018)

PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects
por: Richards, Erica M., et al.
Publicado: (2018)

Comparison of Immuno-PET of CD138 and PET imaging with (64)CuCl(2) and (18)F-FDG in a preclinical syngeneic model of multiple myeloma
por: Bailly, Clément, et al.
Publicado: (2018)

Evaluation of PET Imaging Performance of the TSPO Radioligand [(18)F]DPA-714 in Mouse and Rat Models of Cancer and Inflammation
por: Zheng, Jinzi, et al.
Publicado: (2015)

Comparison of manual and semi-automated delineation of regions of interest for radioligand PET imaging analysis
por: Chow, Tiffany W, et al.
Publicado: (2007)

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau
por: Banka, Vinay, et al.
Publicado: (2023)

LIM Kinases, Promising but Reluctant Therapeutic Targets: Chemistry and Preclinical Validation In Vivo
por: Berabez, Rayan, et al.
Publicado: (2022)

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
por: Bailly, Clément, et al.
Publicado: (2019)

(18)F-Radiolabeled Translocator Protein (TSPO) PET Tracers: Recent Development of TSPO Radioligands and Their Application to PET Study
por: Luu, Truong Giang, et al.
Publicado: (2022)

PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients
por: Bailly, Clément, et al.
Publicado: (2017)

Synthesis and biological evaluation of the new 1,3-dimethylxanthine derivatives with thiazolidine-4-one scaffold
por: Constantin, Sandra, et al.
Publicado: (2017)

Modeling of the Renal Kinetics of the AT1 Receptor Specific PET Radioligand [(11)C]KR31173
por: Gulaldi, Nedim C. M., et al.
Publicado: (2013)

Novel radioligands for imaging sigma-1 receptor in brain using positron emission tomography (PET)
por: Lan, Yu, et al.
Publicado: (2019)

Editorial: Positron Emission Tomography (PET) Imaging of Brain Biochemistry: Beyond High-Affinity Radioligands
por: Kilbourn, Michael R., et al.
Publicado: (2022)

Blocking Studies to Evaluate Receptor-Specific Radioligand Binding in the CAM Model by PET and MR Imaging
por: Löffler, Jessica, et al.
Publicado: (2022)

Metal-Based PSMA Radioligands
por: Gourni, Eleni, et al.
Publicado: (2017)

Neuroprotective and anti-inflammatory effects of a therapy combining agonists of nicotinic α7 and σ1 receptors in a rat model of Parkinson’s disease
por: Vetel, Steven, et al.
Publicado: (2020)

ImmunoPET to help stratify patients for targeted therapies and to improve drug development
por: Kraeber-Bodere, Françoise, et al.
Publicado: (2016)

The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases
por: Dupont, Anne-Claire, et al.
Publicado: (2018)

What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between (89)Zr- and (64)Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model
por: Bailly, Clément, et al.
Publicado: (2019)

Preclinical evaluation of (S)-[(18)F]GE387, a novel 18-kDa translocator protein (TSPO) PET radioligand with low binding sensitivity to human polymorphism rs6971
por: Ramakrishnan, Nisha K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sfs53vqch0l7t7u0vq9k5aodh1